Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors

Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors

ABSTRACT Telisotuzumab vedotin (formerly ABBV‐399) is an antibody‐drug conjugate targeting c‐Met–overexpressing tumor cells, irrespective of MET gene amplification status. Safety, pharmacokinetics, and preliminary efficacy of telisotuzumab vedotin were evaluated outside of Japan. This phase 1 open‐l...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Yutaka Fujiwara, Hirotsugu Kenmotsu, Noboru Yamamoto, Toshio Shimizu, Kan Yonemori, Christopher Ocampo, Apurvasena Parikh, Sumiko Okubo, Kazuteru Fukasawa, Haruyasu Murakami
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Wiley 2021-04-01
Saila:Cancer Medicine
Gaiak:
Antibody‐drug conjugate
Cancer
Clinical trial
c‐Met
Japanese patients
Sarrera elektronikoa:https://doi.org/10.1002/cam4.3815

Internet

https://doi.org/10.1002/cam4.3815

Antzeko izenburuak